HC Wainwright Has Bearish Forecast for APLS FY2028 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $2.35 per share for the year, down from their previous forecast of $2.61. HC Wainwright currently has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ FY2029 earnings at $3.84 EPS.

APLS has been the subject of a number of other research reports. Scotiabank decreased their price objective on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Morgan Stanley began coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target for the company. Wedbush reduced their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday. Oppenheimer decreased their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group dropped their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Monday. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $45.71.

Apellis Pharmaceuticals Stock Down 4.3 %

NASDAQ:APLS opened at $24.06 on Tuesday. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -11.85 and a beta of 0.96. Apellis Pharmaceuticals has a twelve month low of $23.81 and a twelve month high of $66.00. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a fifty day simple moving average of $29.88 and a 200-day simple moving average of $31.48.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.73) EPS.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares in the last quarter. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter worth $27,000. Signaturefd LLC grew its holdings in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $56,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Activity at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares in the company, valued at $1,878,483.60. The trade was a 4.82 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Cedric Francois sold 2,824 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the sale, the chief executive officer now owns 415,695 shares of the company’s stock, valued at approximately $12,271,316.40. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,365 shares of company stock valued at $1,810,479 over the last 90 days. Insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).